Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials

Qi, Wei-Xiang; Shen, Zan; Lin, Feng; Sun, Yaping; Min, Daliu; Tang, Lina; He, Aina; Yao, Yang

doi:10.1185/03007995.2012.756393

Cited by 34 publications

(14 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Approximately 20% to 30% of breast cancer patients present with locally advanced disease, and another 30% of patients will develop recurrent or distant metastatic disease (2). Paclitaxel has been widely used as a chemotherapeutic agent in the treatment of breast cancer and other cancers (3). However, for paclitaxel, substantial toxic effects and a poor response of paclitaxel are still major limitations of treatment in breast cancer (2,4,5).…”

Section: Introductionmentioning

confidence: 99%

Dicer Elicits Paclitaxel Chemosensitization and Suppresses Cancer Stemness in Breast Cancer by Repressing AXL

et al. 2016

View full text Add to dashboard Cite

Paclitaxel is a standard-of-care chemotherapy for breast cancer, despite the increasing recognition of its poor effectiveness in the treatment of patients with advanced disease. Here, we report that adenovirus-type 5 E1A-mediated elevation of the miRNA-processing enzyme Dicer is sufficient to enhance paclitaxel sensitization and reduce cancer stem-like cell properties in this setting. Elevating Dicer expression increased levels of the AXL kinase targeting miRNA miR-494, thereby repressing AXL expression to increase paclitaxel sensitivity. We found that Dicer expression was regulated at the transcription level by E1A, through activation of an MAPK14/CEBPa pathway. Our findings define a mechanism of E1A-mediated chemosensitization for paclitaxel, which is based upon the suppression of breast cancer stem-like cells, with potential implications for the diagnosis and treatment of breast cancer patients. Cancer Res; 76(13); 3916-28. Ó2016 AACR.

show abstract

Section: Introductionmentioning

confidence: 99%

Dicer Elicits Paclitaxel Chemosensitization and Suppresses Cancer Stemness in Breast Cancer by Repressing AXL

et al. 2016

View full text Add to dashboard Cite

show abstract

“…EXE/EVE also appeared to be more efficacious than FEC (95 % CrIs 0.01-0.51) for RR and equal for HR and for PFS/TTP. In the NMA analysis, EXE/EVE is projected to be as efficacious as any of the chemotherapy regimens containing a taxane [17,25]. The combination was slightly inferior to nab-paclitaxel as second-line treatment of MBC [26,27] (95 % CrIs 0.…”

Section: Discussionmentioning

confidence: 99%

A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer

Generali

Venturini

Rognoni

et al. 2015

Breast Cancer Res Treat

View full text Add to dashboard Cite

The goal of this study was to compare the efficacy and toxicity of chemotherapy to exemestane plus everolimus (EXE/EVE) through a network meta-analysis (NMA) of randomized controlled trials. NMA methods extend standard pairwise meta-analysis to allow simultaneous comparison of multiple treatments while maintaining randomization of individual studies. The method enables "direct" evidence (i.e., evidence from studies directly comparing two interventions) and "indirect" evidence (i.e., evidence from studies that do not compare the two interventions directly) to be pooled under the assumption of evidence consistency. We used NMA to evaluate progression-free survival (PFS) and time to progression (TTP) curves in 34 studies, and response rate (RR) and the hazard ratios (HRs) of the PFS/TTP in 36 studies. A number needed to treat (NNT) analysis was also performed as well as descriptive comparison of reported toxicities. The NMA for PFS/TTP curves and for HR shows EXE/EVE is more efficacious than capecitabine plus sunitinib, CMF, megestrol acetate and tamoxifen, with an average of related-PFS/TTP difference ranging from about 10 months for capecitabine plus sunitinib to more than 6 months for tamoxifen. The NMA for overall RR shows that EXE/EVE provides a better RR than bevacizumab plus capecitabine, capecitabine, capecitabine plus sorafenib, capecitabine plus sunitinib, CMF, gemcitabine plus epirubicin plus paclitaxel, EVE plus tamoxifen, EXE, FEC, megestrol acetate, mitoxantrone, and tamoxifen. Finally, the NMA for NNT shows that EXE/EVE is more beneficial as compared to BMF, capecitabine, capecitabine plus sunitinib, CMF, FEC, megestrol acetate, mitoxantrone, and tamoxifen. The combination of EXE/EVE as first- or second-line therapy for ER+ve/HER2-ve metastatic breast cancer is more efficacious than several chemotherapy regimens that were reported in the literature. Toxicities also favored EXE/EVE in most instances.

show abstract

“…The two taxanes have been observed to have comparable efficacy. Although efficacy between the two agents has been observed to be equivalent, paclitaxel may cause fewer sideeffects [13]. Additionally, it has been noted that docetaxel is prone to cellular drug resistance via a variety of different mechanisms [14].…”

Section: Taxanesmentioning

confidence: 99%

Mechanisms of breast cancer resistance to anthracyclines or taxanes

Zha

Zhao

et al. 2015

Current Opinion in Oncology

View full text Add to dashboard Cite

show abstract

Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials

Cited by 34 publications

References 31 publications

Dicer Elicits Paclitaxel Chemosensitization and Suppresses Cancer Stemness in Breast Cancer by Repressing AXL

Dicer Elicits Paclitaxel Chemosensitization and Suppresses Cancer Stemness in Breast Cancer by Repressing AXL

A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer

Mechanisms of breast cancer resistance to anthracyclines or taxanes

Contact Info

Product

Resources

About